- Net Income: Wantai Bio’s net income for the third quarter is reported at 6.17 million yuan.
- Revenue: The company earned 582.1 million yuan in revenue during the same period.
- Investment Ratings: The company has received different investment ratings, including four “buy” recommendations, one “hold,” and one “sell”
A look at Beijing Wantai Biological Phar Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., a company that manufactures medical products including diagnostic reagents, vaccines, and biochemical reagents, is positioned for long-term success according to Smartkarma Smart Scores. With a positive outlook for resilience and growth, the company’s solid score reflects its ability to withstand challenges and maintain growth potential in the evolving market.
While the Value and Dividend scores are moderate, the higher scores in Resilience and Growth factors, along with a decent momentum score, signify promising prospects for Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. These scores indicate a company that is well-prepared to handle disruptions and capitalize on growth opportunities, making it an intriguing option for long-term investors looking for stability and potential for expansion.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
